Merck's Keytruda nabs melanoma nod in EU; AstraZeneca's MEK inhibitor fails late-stage melanoma trial;

> Merck ($MRK) won European approval for its closely watched cancer immunotherapy Keytruda, for use in patients with advanced melanoma who haven't yet been treated or who've failed on previous therapy; the drug won U.S. approval last year. Release

> AstraZeneca ($AZN) said its new cancer treatment selumetinib, a MEK inhibitor, fell short in a Phase III trial in uveal melanoma patients; testing is ongoing in a variety of other cancer types. Release

> With HIV treatments readily available in low-income countries, Doctors Without Borders is shifting its attention to broadening access to the meds in middle-income countries where cut-rate generic programs don't apply. Release

> Patients using the diabetes drugs Avandia (rosiglitazone) and Actos (pioglitazone) had a 28% lower incidence of Parkinson's disease, a study found; researchers said the results should prompt new studies into the drugs' mechanisms. Report

> Merck broadened its nanobody medicines collaboration with Belgium-based Ablynx, adding 12 new programs and boosting the total potential milestones to about 4 billion euros. Report

And Finally... The first U.S. drug delivery by drone happened in Virginia, in a test of the technology for transporting medical supplies to remote areas. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.